Olpruva Kit
NDC Package 72542-600-18
Package Information
Olpruva (sodium phenylbutyrate) kits is a medication used along with diet changes for long-term treatment of a certain inherited disorder (urea cycle disorder). This formulation utilizes a kit delivery system. Marketed by Acer Therapeutics Inc., this product is identified by NDC 72542-600 and is authorized under FDA application NDA214860.
Identification & Billing
- RxCUI: 2626369 - sodium phenylbutyrate 2 GM Granules for Oral Suspension
- RxCUI: 2626369 - sodium phenylbutyrate 2000 MG Granules for Oral Suspension
- RxCUI: 2626375 - OLPRUVA 2 GM Granules for Oral Suspension
- RxCUI: 2626375 - sodium phenylbutyrate 2000 MG Granules for Oral Suspension [Olpruva]
- RxCUI: 2626375 - Olpruva 2 GM Granules for Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72542 - Acer Therapeutics Inc.
- 72542-600 - Olpruva
- 72542-600-18 - 90 BOX in 1 CARTON / 1 KIT in 1 BOX (72542-600-02) * 1 FOR SUSPENSION in 1 PACKET (72542-003-01) * 1 FOR SUSPENSION in 1 PACKET (72542-000-01)
- 72542-600 - Olpruva
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72542-600-18 identifies a specific commercial package of 90 box in 1 carton / 1 kit in 1 box (72542-600-02) * 1 for suspension in 1 packet (72542-003-01) * 1 for suspension in 1 packet (72542-000-01) of Olpruva, a human prescription drug labeled by Acer Therapeutics Inc.. This kit is formulated for oral use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Acer Therapeutics Inc. on December 22, 2022. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used along with diet changes for long-term treatment of a certain inherited disorder (urea cycle disorder). It helps remove a certain chemical (ammonia) from the body. Too much ammonia in the body can cause brain damage and sometimes death. This medication should not be used to treat sudden, severely high levels of ammonia in the body. Seek immediate medical attention if you have sudden symptoms of too much ammonia, such as trouble thinking, vomiting, irritability, trouble speaking, trouble walking, fainting.
How is this Acer Therapeutics Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72542060018. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.